Evidence map›Paper›PMID 38807451›Full record

SynthesisJournal of cutaneous medicine and surgery

Efficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review.

Ryan S Q Geng, Siddhartha Sood, Nicholas Hua, Jennifer Chen, Ronald G Sibbald, Cathryn Sibbald

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The exposomal imprint on rosacea: More than skin deep.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  2. Formulation and Biological Evaluation ofAntioxidants (Basel, Switzerland) · 2026
    Article
  3. Rosacea in childhood and adolescence: A review.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryan S Q GengTemerty School of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-4387-095X
Siddhartha SoodTemerty School of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-3531-5961
Nicholas HuaTemerty School of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0009-0003-8503-0056
Jennifer ChenTemerty School of Medicine, University of Toronto, Toronto, ON, Canada.
Ronald G SibbaldDalla Lana School of Public Health and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6060-7272
Cathryn SibbaldDivision of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRosacea is a chronic inflammatory skin condition affecting approximately 5.5% of the global population. Patients present heterogeneously with a mix of features in the central facial region, of which papules and pustules are considered to be a major feature. The identification of effective treatments for reducing inflammatory lesions in rosacea can alleviate the psychosocial burden that many rosacea patients experience, including reduced self-esteem, anxiety, and social withdrawal. The objective of this systematic review is to determine the effectiveness of topical and systemic therapies in reducing lesion count in rosacea patients. METHODS/

resultsMedline, Embase, and Cochrane CENTRAL databases were searched, resulting in the inclusion of 43 clinical trials reporting on a total of 18,347 rosacea patients. The most well-studied treatments include ivermectin, metronidazole, azelaic acid, minocycline, and doxycycline. Oral isotretinoin was the most effective treatment in reducing inflammatory lesions and may be recommended for severe recalcitrant cases of rosacea.

conclusionsSeveral topical and systemic therapies have demonstrated efficacy in reducing inflammatory lesion count in rosacea patients, with mechanisms of action centred around suppressing inflammation and killing

Indexed as

Dermatologic AgentsRosaceaDicarboxylic AcidsHumansIsotretinoinIvermectinMetronidazoleazelaic acidDermatologic AgentsDicarboxylic AcidsIsotretinoinIvermectinMetronidazoledemodexinflammatory lesionsrosacea

Identifiers

PMID38807451
PMCPMC11408985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.